CING fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
CING does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company